ストックスクリーナーアプリを入手
385.65
1.55%
5.87
プレマーケット:
386.82
1.17
+0.30%
前日終値:
$379.78
開ける：
$378.51
24時間の取引高:
8.47M
Relative Volume:
3.17
時価総額：
$208.49B
収益：
$37.30B
当期純損益:
$7.80B
株価収益率:
26.82
EPS:
14.3793
ネットキャッシュフロー:
$8.60B
1週間 パフォーマンス:
+2.20%
1か月 パフォーマンス:
-9.32%
6か月 パフォーマンス:
+9.72%
1年 パフォーマンス:
+39.81%
1日の値動き範囲:
$378.51
$386.50
1週間の範囲:
$374.46
$386.50
52週間の値動き範囲:
$269.77
$447.03
Amgen Inc Stock (AMGN) Company Profile
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
385.65 | 204.01B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,152.93 | 994.49B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
269.99 | 640.02B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
263.96 | 454.36B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
146.87 | 355.10B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
140.37 | 260.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-21 | 開始されました | Canaccord Genuity | Hold |
| 2026-03-10 | 開始されました | Jefferies | Hold |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-01-20 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-12-05 | アップグレード | Erste Group | Hold → Buy |
| 2025-11-24 | 再開されました | Truist | Hold |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-09-03 | 再開されました | Raymond James | Mkt Perform |
| 2025-05-20 | 再開されました | Guggenheim | Neutral |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-14 | ダウングレード | Truist | Buy → Hold |
| 2024-09-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | アップグレード | Barclays | Underweight → Equal Weight |
| 2024-05-03 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 再開されました | Raymond James | Mkt Perform |
| 2024-02-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-02 | アップグレード | Truist | Hold → Buy |
| 2023-10-20 | 再開されました | JP Morgan | Neutral |
| 2023-10-17 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 再開されました | BofA Securities | Neutral |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-04-24 | 繰り返されました | Oppenheimer | Outperform |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 繰り返されました | Truist | Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Underperform |
| 2022-10-31 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2022-10-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-09 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-09 | 繰り返されました | Jefferies | Buy |
| 2022-02-09 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-09 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-09-23 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 開始されました | Daiwa Securities | Buy |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-10-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | アップグレード | Truist | Hold → Buy |
| 2020-10-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | ダウングレード | Truist | Buy → Hold |
| 2020-10-08 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 再開されました | Guggenheim | Neutral |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-03-30 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-17 | 再開されました | Morgan Stanley | Overweight |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-11-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-08-19 | ダウングレード | Mizuho | Buy → Neutral |
| 2019-05-23 | アップグレード | Citigroup | Neutral → Buy |
すべてを表示
Amgen Inc (AMGN) 最新ニュース
Advancing Innovation in Small Cell Lung Cancer at WCLC 2026 – Amgen - Oncodaily
Amgen stock falls after HSBC downgrade and strong Q2 figures - ad-hoc-news.de
Is Amgen (AMGN) Fully Valued As New IMDELLTRA Data Reshapes The Story? - simplywall.st
Amgen stock falls after HSBC cuts its rating - ad-hoc-news.de
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure - Yahoo Finance
Corient Private Wealth LP Decreases Position in Amgen Inc. $AMGN - MarketBeat
Does Amgen (AMGN) Change The Oncology Case With This Phase 3 Survival Win? - simplywall.st
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Chip stocks lead Nasdaq's weekly gains; Amgen plunges after trial setback - TradingView
Amgen Highlights 26% Growth Drivers, IMDELLTRA Momentum and MariTide Potential - Yahoo Finance
Amgen Drops 10% on a Trial It Didn't Even Run - MarketBeat
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Positive Lung Cancer Data Lifts the Case for Amgen and AstraZeneca - Yahoo Finance
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Are Medical Stocks Lagging Amgen (AMGN) This Year? - Yahoo Finance
Amgen stock falls as HSBC downgrade and lower price target weigh on shares - ad-hoc-news.de
Amgen Inc. $AMGN Shares Sold by The Manufacturers Life Insurance Company - MarketBeat
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use - Yahoo Finance
Why Is the Market Watching Amgen (AMGN)? - Kalkine Media
Amgen stock heads into the open after a 2.25% drop - ad-hoc-news.de
Amgen (AMGN) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Stock Traders Buy Large Volume of Put Options on Amgen (NASDAQ:AMGN) - MarketBeat
AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study - The Globe and Mail
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Amgen’s New Repatha Plaque Trial: What Investors Should Watch - TipRanks
Amgen at Wells Fargo 21st Annual Healthcare Conference: growth broadens By Investing.com - Investing.com India
Amgen Inc at Wells Fargo Healthcare Conference Transcript - GuruFocus
Amgen stock dips as HSBC cuts rating and trims price target - ad-hoc-news.de
Amgen (AMGN) Stock Looks Cheap Relative To Fair Value - simplywall.st
HSBC Downgrades Amgen to Hold From Buy, Adjusts Price Target to $425 From $445 - marketscreener.com
Amgen Stock: Buy The Novartis-Driven Selloff (Rating Upgrade) (NASDAQ:AMGN) - Seeking Alpha
Sequoia Financial Advisors LLC Boosts Stock Holdings in Amgen Inc. $AMGN - MarketBeat
National Pension Service Has $465.74 Million Stake in Amgen Inc. $AMGN - MarketBeat
NewEdge Advisors LLC Has $33.69 Million Holdings in Amgen Inc. $AMGN - MarketBeat
AMGN - Finviz
HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review By Investing.com - Investing.com South Africa
HSBC downgrades Amgen stock rating to Hold on valuation - investing.com
HSBC downgrades Amgen stock rating to Hold on valuation By Investing.com - Investing.com Canada
Amgen stock heads into the open after a 10.1 percent drop - ad-hoc-news.de
Amgen’s Forward Multiple Looks Cheap Until You Price The Margins It Assumes - Trefis
Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)? - Yahoo Finance
AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE - PR Newswire
Amgen's Imdelltra Sales Surge 115% as Lung-Cancer Combination Me - GuruFocus
Gordon Reid's Past Picks: Amgen, Qualcomm & United Rentals - BNN Bloomberg
Amgen’s Phase III DeLLphi-305 study deliverers strong results - thepharmaletter.com
Amgen's Imdelltra scores again in small cell lung cancer - pharmaphorum
Amgen stock falls sharply as trial read-through and Tavneos risk unsettle investors - ad-hoc-news.de
Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study - Yahoo Finance
Amgen and AstraZeneca report survival improvement in lung cancer trial - Yahoo Finance UK
Amgen Stock Sank 9.6% After Novartis’s Trial Failure and a Tavneos Suspension - TIKR.com
Amgen Inc (AMGN) 財務データ
収益
当期純利益
現金流量
EPS
Amgen Inc (AMGN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Khosla Rachna | SVP, Business Development |
Aug 11 '26 |
Sale |
412.57 |
2,000 |
825,134 |
6,404 |
| Khosla Rachna | SVP, Business Development |
Aug 13 '26 |
Sale |
416.43 |
1,252 |
521,365 |
6,404 |
0.12%
0.52%
大文字化:
|
ボリューム (24 時間):